Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma

Hideomi Yamashita1*, Hiroshi Onishi2, Naoya Murakami3, Yasuo Matsumoto4, Yukinori Matsuo5, Takuma Nomiya6 and Keiichi Nakagawa1, Japanese Radiological Society multi-institutional SBRT study group (JRS-SBRTSG)

1Department of Radiology, University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655 Japan
2Department of Radiology, Yamanashi University
3Department of Radiology, National Cancer Center Hospital
4Department of Radiology, Niigata University School of Medicine
5Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan
6Department of Radiology, Yamagata University Hospital

*Corresponding author. Department of Radiology, University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655 Japan. Tel: +81-3-5800-8667; Fax: +81-3-5800-8935; Email: yamachan07291973@yahoo.co.jp

Received September 13, 2014; Revised November 24, 2014; Accepted December 24, 2014

ABSTRACT

Stereotactic body radiotherapy (SBRT) is a relatively new treatment for liver tumor. Outcomes of SBRT for liver tumors unsuitable for ablation or surgical resection were evaluated.

A total of 79 patients treated with SBRT for primary hepatocellular carcinoma (HCC) between 2004 and 2012 in six Japanese institutions were studied retrospectively. Patients treated with SBRT preceded by trans-arterial chemoembolization were eligible. Their median age was 73 years, 76% were males, and their Child–Pugh scores were Grades A (85%) and B (11%) before SBRT. The median biologically effective dose ($\alpha/\beta = 10$ Gy) was 96.3 Gy.

The median follow-up time was 21.0 months for surviving patients. The 2-year overall survival (OS), progression-free survival (PFS), and distant metastasis-free survival were 53%, 40% and 76%, respectively. Sex and serum PIVKA-II values were significant predictive factors for OS. Hypovascular or hypervascular types of HCC, sex and clinical stage were significant predictive factors for PFS. The 2-year PFS was 66% in Stage I vs 18% in Stages II–III. Multivariate analysis indicated that clinical stage was the only significant predictive factor for PFS. No Grade 3 laboratory toxicities in the acute, sub-acute, and chronic phases were observed.

PFS after SBRT for liver tumor was satisfactory, especially for Stage I HCC, even though these patients were unsuitable for resection and ablation. SBRT is safe and might be an alternative to resection and ablation.

KEYWORDS: hepatocellular carcinoma, stereotactic body radiotherapy, SBRT

INTRODUCTION

In Japan, the infection rate of hepatitis C is high, with many cases of hepatocellular carcinoma (HCC) [1]. According to clinical practice guidelines from Japan, resection, radiofrequency ablation (RFA), and liver transplantation are the curative options available for HCC [2]. Recently, stereotactic body radiotherapy (SBRT) has become a treatment option for patients with liver tumors who are not eligible for surgery, RFA, or liver transplantation [3]. HCC has good radiation sensitivity [4]. However, currently SBRT of the liver is not frequently performed. This is because radiotherapy (RT) for liver tumors has been limited due to the risk of radiation-induced liver disease (RILD) [5]. However, technological advances have made it possible for radiation to be delivered to small liver tumors, while reducing the risk of RILD [6]. Resection, RFA, or transcatheter arterial chemoembolization (TACE) are often performed for HCC in Japan. However, only 10–20% of HCC patients have
Resectable disease [7]. A drawback for RFA is that the procedure is difficult to perform in some anatomic areas [8]. Patients who are introduced to SBRT consist only of those with a central lesion of the liver, with direct invasion into the vessels, and/or with an insufficient outcome from TACE. In patients with centrally located HCC with chronic hepatitis or cirrhosis, major resection is often contraindicated due to insufficient residual liver volume [9]. RFA is therefore often contraindicated for HCC in those areas that are located in and near the hepatic portal vein or the central bile duct [10] and abutting the diaphragm [8]. Additionally, the risk of neoplastic seeding along the needle track after RFA has been reported [11].

The purpose of this study was to retrospectively evaluate the outcomes, mainly concerning survival, for patients treated at various dose levels in several Japanese institutions, although the local control rate has been reported elsewhere [12]. Because of the small number of cases of liver SBRT performed in each institution, it was necessary to gather results and data on side effects from many institutions in order to obtain meaningful information.

MATERIALS AND METHODS

Patients
This retrospective study reviewed data extracted from the database of the Japanese Radiological Society multi-institutional SBRT study group (JRS-SBRTSG) for 79 patients with HCC treated at six institutions (27, 19, 14, 9, 5 and 5 cases). The investigation period was from May 2004 to November 2012.

The diagnosis of HCC depended primarily on imaging studies, because pathological confirmation was not feasible in the candidates for SBRT. During follow-up of patients with liver disease, nodules \( \geq 1 \) cm were diagnosed as HCC based on the typical hallmarks. These included being hypervascular in the arterial phase, with washout in the portal, venous or delayed phases about hypervascular HCC and, on the other hand, less-than-subtle density area in delayed phases and showing enlargement, plethoric change, and/or MRI signal change during long-time follow-up about hypovascular HCC from imaging studies. The imaging techniques included a combination of contrast-enhanced ultrasonography, 4-phase multi-detector computed tomography (CT), dynamic contrast-enhanced magnetic resonance imaging (MRI), and CT during hepatic arteriography and arterio-portography studies. The diagnosis was established according to a review of the imaging studies [13] and clinical practice guidelines [14–15]. The eligibility for SBRT for HCC was a single lesion. The version of staging classification used in this paper was the UICC classification version 7.

Patient and tumor characteristics are shown in Table 1. With regard to Child–Pugh scores before liver SBRT, 84.8% of patients had Grade A, 11.4% had Grade B, and 1.3% had Grade C. Hypovascular HCC was found in 16/79 cases (20%) and hypervascular HCC was found in 55/79 cases (70%). The feature of vascularity for the remaining eight patients was not evaluable in five patients, was unclear in one patient, and was not detectable by CT in two patients. The median alpha-fetoprotein (AFP) (ng/ml) and des-gamma carboxy prothrombin (PIVKA-II) (AU/ml) values before liver SBRT for 73 evaluable patients were 12.7 ng/ml (range, 0.8–8004) and 35 AU/ml (range, 3.1–16 900), respectively. The median indocyanine green retention rate at 15 min (ICG15) before liver SBRT for 25 evaluable patients was 21.2% (range, 3.0–56.2%). Liver SBRT was the first treatment in 26/79 cases (33%) and was also the first treatment for ectopic recurrences of liver SBRT in an additional seven cases.

| Table 1. Patient and tumor characteristics of SBRT |
| --- |
| Factors | \( n \) | Rate |
| All patients | 79 | 100% |
| Stage |  |  |
| I | 29 | 37% |
| II | 21 | 27% |
| III | 7 | 9% |
| Recurrence | 11 | 14% |
| NE | 11 | 14% |
| Child–Pugh before SBRT |  |  |
| A | 67 | 85% |
| B | 9 | 11% |
| C | 1 | 1% |
| NE | 2 | 3% |
| Sex |  |  |
| Female | 19 | 24% |
| Male | 60 | 76% |
| Tumor maximum diameter (mm) |  |  |
| Range | 6–70 |  |
| Median | 27 |  |
| Performance status (ECOG) |  |  |
| 0 | 34 | 43% |
| 1 | 39 | 49% |
| 2 | 4 | 5% |
| 3 | 1 | 1% |
| Age (years old) |  |  |
| Range | 38–95 |  |
| Median | 73 |  |
| SRT total dose (Gy) |  |  |
| Range | 40–60 |  |
| Median | 48 |  |
| BED-10 (Gy) |  |  |
| Range | 75–106 |  |
| Median | 96.3 |  |
| Factors                        | 2-year OS | P-value by log-rank | 2-year PFS | P-value by log-rank |
|-------------------------------|-----------|---------------------|------------|---------------------|
| **Chemotherapy**              |           |                     |            |                     |
| With                          | 47.6 ± 18.7 | 0.10               | 41.4 ± 7.1 | 0.75               |
| Without                       | 53.6 ± 7.6  |                    | 24.1 ± 19.5 |                   |
| **Tumor diameter**            |           |                     |            |                     |
| Over 30 mm                    | 55.9 ± 10.2 | 0.70               | 35.0 ± 9.2 | 0.34               |
| Under 30 mm                   | 50.3 ± 10.7 |                    | 50.3 ± 9.8 |                     |
| **HCC type**                  |           |                     |            |                     |
| Hypovascular                  | 43.2 ± 20.8 | 0.86               | 22.2 ± 13.0 | 0.040              |
| Hypervascular                 | 51.6 ± 8.4  |                    | 44.2 ± 8.2  |                     |
| **Child–Pugh Grade**          |           |                     |            |                     |
| A                             | 53.6 ± 8.0  | 0.13               | 40.5 ± 7.5 | 0.22               |
| B–C                           | 30.3 ± 17.1 |                    | 36.0 ± 16.1 |                   |
| **Sex**                       |           |                     |            |                     |
| Female                        | 78.4 ± 11.2 | 0.044              | 67.6 ± 12.1 | 0.049              |
| Male                          | 43.1 ± 8.4  |                    | 30.3 ± 7.7  |                     |
| **Serum AFP value**           |           |                     |            |                     |
| Over 20                       | 52.3 ± 10.9 | 0.81               | 42.1 ± 10.2 | 0.59               |
| Under 20                      | 54.8 ± 9.9  |                    | 45.3 ± 9.6  |                     |
| **Serum PIVKA-II**            |           |                     |            |                     |
| Over 35                       | 44.7 ± 10.6 | 0.039              | 32.5 ± 9.8  | 0.16               |
| Under 35                      | 69.7 ± 9.9  |                    | 54.4 ± 9.8  |                     |
| **BED (Gy)**                  |           |                     |            |                     |
| Over 100                      | 48.1 ± 10.4 | 0.28               | 41.8 ± 10.2 | 0.99               |
| Under 100                     | 57.2 ± 9.7  |                    | 39.2 ± 8.8  |                     |
| **Age (years old)**          |           |                     |            |                     |
| Over 75                       | 56.7 ± 10.2 | 0.80               | 54.4 ± 9.3  | 0.58               |
| Under 75                      | 49.7 ± 9.8  |                    | 30.2 ± 8.6  |                     |
| **Hilum LN metastasis**       |           |                     |            |                     |
| With                          | 50.0 ± 35.4 | 0.32               | 0 ± 0      | 0.12               |
| Without                       | 53.5 ± 7.3  |                    | 41.9 ± 6.9  |                     |
| **Clinical stage**            |           |                     |            |                     |
| I                             | 58.2 ± 10.8 | 0.40               | 66.3 ± 9.3  | 0.007              |
| II-                           | 50.0 ± 10.9 |                    | 18.4 ± 8.0  |                     |

*Continued*
Table 2. Continued

| Factors          | 2-year OS  | P-value by log-rank | 2-year PFS | P-value by log-rank |
|------------------|------------|---------------------|------------|---------------------|
| Primary effect   |            |                     |            |                     |
| PR/Cr            | 56.8 ± 7.8 | 0.44                | 42.9 ± 7.5 | 0.24                |
| NC/PD            | 38.7 ± 19.5| 0.15                | 28.7 ± 15.3| 0.26                |
| Performance status |          |                     |            |                     |
| 0–1              | 54.5 ± 7.6 |                     | 37.6 ± 6.9 |                     |
| 2–                | 50.0 ± 25.0|                     | 50.0 ± 25.0|                     |

OS = overall survival, PFS = progression-free survival, HCC = hepatic cell carcinoma, AFP = α-fetoprotein, PIVKA = protein induced by vitamin K absence or antagonist, PR = partial response, CR = complete response, NC = no change, PD = progressive disease.

**Treatment**

For treatment planning, abdominal pressure corsets such as a body shell (19 cases) and vacuum cushion (59 cases) such as blue back (5 cases), Vac-Lok (13 cases), or Body-Fix (5 cases) were used. In one case, none was used. Tumor motion was confirmed at < 1 cm in the cases using abdominal pressure. The gross tumor volume was delineated on both inspiratory and expiratory planning CT images by the respiratory depression method. The breath-holding method was used in 43 cases, the gating method in 10 cases, and the respiratory depression method in 25 cases. One patient was treated with free-breathing. The planning target volume was configured considering respiratory movement, the set-up margin, and the sub-clinical margin. SBRT was performed with an X-ray beam linear accelerator of 6 MV. The total irradiation dose delivered was dependent on the judgment rendered at each institution. A collapsed cone convolution, superposition algorithm, or analytical anisotropic algorithm was used for dose calculations.

The mode value of the total irradiation dose was 48 Gy in 4 fractions (38/79 cases) (from 40 Gy in 4 fractions to 60 Gy in 10 fractions). The prescription point was D95 (dose covering 95% volume within the PTV) in 48 patients (61%) and the iso-center in 31 patients (39%). The biologically effective dose (BED) (α/β = 10 Gy) was 75–106 Gy (median: 96 Gy) (Table 1). The following formula for BED10 was used: BED (Gy10) = nd × (1 + d/10). In all cases, CT registration such as kV cone beam CT or on-rail CT was performed during each treatment.

SBRT was delivered using multiple non-coplanar static beams (using >7 non-coplanar beams) generated by a linear accelerator or volumetric-modulated arc therapy. Daily image guidance, by using either orthogonal X-rays or onboard CT imaging, was used to re-localize the target before treatment delivery.

In seven patients, TACE was performed before SBRT. Oral tegafur/CDHP/oteracil potassium (S-1) was combined concurrently with liver SBRT in one patient.

**Follow-up**

Patients were examined every 1 to 3 months for 1 year after liver SBRT and tri-monthly thereafter. Laboratory tests were performed at every visit. Treatment responses and intrahepatic recurrences were evaluated with dynamic contrast-enhanced CT or MRI every 3 months according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) [16]. Toxicity was evaluated with the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. Acute and sub-acute toxicities were defined as adverse events occurring within 3 months and 3 to 6 months, respectively, after liver SBRT. Late toxicities related to liver and other toxicities were defined as those occurring after 6 to 12 months and from 6 months to the last follow-up, respectively. Laboratory tests included determinations of aspartate aminotransferase, total bilirubin, platelet count, and albumin.

**Statistical analysis**

Survival rates were calculated by Kaplan–Meier analysis. Log-rank testing was used to compare outcomes between the subsets of patients analyzed. Cox proportional hazards regression analysis was used for multivariate analysis. A P-value of < 0.05 was considered significant. Data were analyzed with SPSS Statistics 20.0 (IBM Corp., Armonk, NY, USA). The points on survival curves by Kaplan–Meier were censored cases.

**RESULTS**

**Eligible patients**

The median follow-up time was 21.0 months (range, 3.4–68.3 months) for surviving patients. SBRT was performed as scheduled and was feasible in all patients. At the last follow-up, 48 cases (61%) had survived and 31 cases (39%) were deceased.

**Treatment outcomes**

The first local effect was complete response in 36 cases (46%), partial response in 28 cases (35%), no change in 9 cases (11%), progressive disease in 4 cases (5%), and not evaluable in 2 cases (3%). At censoring during the follow-up, 14 cases (18%) had local progression, 63 cases (80%) did not have local progression, and 2 cases (3%) were not evaluable.

For the 79 patients, the 2-year overall survival (OS), progression-free survival (PFS), and distant metastatic-free survival (DMF) were 52.9% ± 7.1%, 39.9% ± 6.9%, and 76.3% ± 6.6%, respectively. The number of patients at risk was 43 (54%), 21 (27%), 9 (11%), and 3 (4%) at 1-, 2-, 3- and 4-years in OS, respectively.

The results of sub-analysis of survival are shown in Table 2. Sex (female vs male) and serum PIVKA-II value (over 35 vs under 35)
were significant predictive factors for 2-year OS ($P = 0.044$ and $0.039$, respectively) by the log-rank test. HCC type (hypovascular vs hypervascular) (Fig. 2), sex (female vs male), and clinical stage (I vs II–III) (Fig. 3) were significant predictive factors for 2-year PFS ($P = 0.040, 0.049$ and $0.007$, respectively) by the log-rank test.

By multivariate analysis (Cox proportional hazards regression analysis), clinical Stage I vs II–III (other covariates were male vs female and PIVKA-II > 35 vs < 35) was the only significant predictive factor for PFS ($P = 0.017, 95\% \text{ CI} = 0.190–0.848$) (Table 3). No differences in predictive factors were shown for OS and PFS, even when other factors such as tumor diameter $\geq 30$ mm vs $<30$ mm, hypervascular vs hypovascular HCC by CT scan, and BED$_{10} \geq 100$ Gy vs $<100$ Gy were added to the analysis.

### Treatment-related toxicity

All liver SBRTs were completed without toxicity during the RT period. There was no Grade 5 toxicity. After the RT period, six patients (4.6%) experienced Grade 3–4 gastrointestinal toxicity and three patients (2.3%) had Grade 2 gastrointestinal toxicity. With regard to Grade 3–4 toxicities, duodenal ulcer, transverse colon ulcer, gastroduodenal aorta rupture, biliary stricture after SBRT occurred in one patient, respectively, and gastrointestinal bleeding in two patients. Only the gastroduodenal aorta rupture was Grade 4 toxicity. Of these nine patients, seven had a Child–Pugh score of Grade A, and the other two patients had a Child–Pugh score of Grade B before SBRT. No significant ($\geq$ Grade 3) liver enzyme elevation was observed during treatment, nor was classic RILD observed.

### DISCUSSION

This is a retrospective study that reviewed data extracted from the database of JRS-SBRTSG for 79 patients with HCC treated at six institutions. The OS of 53% in this study at 2 years after liver SBRT might be considered satisfactory considering that the patient group included frail patients for whom surgery was contraindicated due to

---

**Fig. 1.** Overall survival curves by serum PIVKA-II value (over 35 vs under 35 AU/ml). There was no patient with serum PIVKA-II level of just 35 AU/ml.

**Fig. 2.** Progression-free survival curves by HCC type (hypovascular vs hypervascular).

**Fig. 3.** Progression-free survival curves by clinical stage (I vs II–III).

**Table 3. Multivariate analysis for survival**

| Factors          | OS P-value | 95% CI     | PFS P-value | 95% CI     |
|------------------|------------|------------|-------------|------------|
| Stage            | 0.47       | 0.017      | 0.017       | 0.017      |
| I                | 0.303–1.730| 0.190–0.848| 1           | 1          |
| II–III           | 1          | 1          | 1           | 1          |
| Sex              | 0.29       | 0.36       | 0.36        | 0.36       |
| Male             | 1          | 1          | 1           | 1          |
| Female           | 0.123–1.871| 0.246–1.665| 0.246–1.665| 0.246–1.665|
| PIVKA-II         | 0.28       | 0.56       | 0.56        | 0.56       |
| Over 35          | 0.656–4.330| 0.604–2.547| 0.604–2.547| 0.604–2.547|
| Under 35         | 1          | 1          | 1           | 1          |

OS = overall survival, PFS = progression free survival.
decompensated cirrhosis and who were in an older age group (median age 73 years). Patients in this study were very heterogeneous, and some patients might not have been candidates for SBRT according to strict guidelines. Survival data was the only factor analyzed in this study.

Survival data after SBRT for liver tumor from previous reports are summarized in Table 4. According to those reports, the 2-year OS was 34% [15], 52% [16], 55% [21], 60% [18], 67% [20] and 83% [19]. The 2-year OS was 53% in the present study, which cannot be viewed as a satisfactory result. In order to improve our results for survival, an increase in the radiation dose may be required, although BED10 was not the factor for survival in the present study (Table 2). The median BED10 in this study was 96 Gy; therefore, over half of the patients received a BED10 of <100 Gy. Dose escalation for HCC patients with decompensated cirrhotic liver disease may be deleterious with respect to normal liver tolerance. Takeda et al. [23] used 35–40 Gy in five fractions (59.5–72.0 Gy in BED10), based on baseline liver function and on liver volume receiving ≥20 Gy (V20) in SBRT for untreated solitary HCC patients. They reported relatively good results, in which the 2-year local control rate and OS were 95% and 87%, respectively [23], although the BED10 was not very high. In their paper [23], the doses were prescribed to the planning target volume surface. In the present study, on the other hand, the doses were prescribed to the PTV-D95 (61%) or the iso-center (39%).

By multivariate analysis, clinical Stage I vs Stage II–III was the only significant prognostic factor for PFS. The main prognostic factors of HCC reported previously included stage classification, invasion to a blood vessel, liver function, tumor diameter, or the number of tumors [24–26]. However, in our study, clinical stage was found to be the sole prognostic factor.

Guidelines for HCC diagnosis indicate that a pathological diagnosis is not necessary if a tumor has a typical radiographic appearance. In this study, 20% of the patients had hypovascular HCC, and most of these HCC lesions were diagnosed by 18fluorine-fluorodeoxyglucose positron-emission tomography study and the α-fetoprotein tumor marker of the L3 fraction. The reason for the poorer survival of patients with the hypovascular type of HCC than patients with the hypervascular type was not clear. Usually, hypovascular HCC is at an earlier stage and has a good prognosis. This reason why hypovascular HCC had a poorer prognosis may be that many cases of hypovascular HCC in this study had been observed without immediate treatment until size-up, plethoric change, and/or MRI signal change, as stated above.

Only one patient with Child–Pugh Grade C was treated with SBRT in this study. In that patient, there was no other treatment option, and the patient was informed of the risks of the procedure and provided consent.

There are some limitations in this study in that it is retrospective and part of a multi-institutional series with a relatively short follow-up period (median 15 months). In addition, the irradiation dose and follow-up methods were inconsistent. The reason for the lack of difference according to the stratification of the irradiation dose may be due to the various algorithms or to the differing prescription points between institutions.

Table 4. Previous reports on survival after SBRT for HCC

| Year | Ref | Dose | Subject | n  | MST (mo) | OS  | PFS  | Median size | Child |
|------|-----|------|---------|----|---------|-----|------|-------------|-------|
| 2008 | [17]| Median 36 Gy/6 Fr | HCC    | 31 | 11.7    | 1 year: 48% | 173 cm³ |
| 2010 | [18]| Median 36 Gy/3 Fr | HCC    | 17 |         | 1 year: 75% |       |
| 2010 | [19]| 30–39 Gy       | HCC    | 42 |         | 1 year: 93% | 15.4 cm³ |
| 2010 | [16]| 45 Gy/3 Fr by Cyber |     |    | 1 year: 79% | 4.5 cm | A: 48% |
| 2011 | [20]| Median 44 Gy/3 Fr |       | 60 | 2 year: 67% | 2 year: 48% | 3.2 cm | A: 60% |
| 2012 | [21]| Median 30 Gy/15 Fr | HCC    | 21 | 1 year: 87% |       |       |
| 2013 | [15]| Median 36 Gy/6 Fr | ICC    | 11 | 2 year: 55% |       |       |
| 2013 | [22]| Median 60 Gy    | HCC    | 14 | 1 year: 83% |       |       |

MST = median survival time, OS = overall survival, PFS = progression-free survival, Child = Child–Pugh Grade.
CONCLUSION
Overall survival after SBRT for liver tumor was satisfactory, especially in Stage I HCC, despite the candidates being unsuitable for resection and ablation. SBRT is safe and might be an alternative method to resection and ablation.

FUNDING
Funding to pay the Open Access publication charges for this article was provided by KAKENHI of Grants-in-Aid for Scientific Research.

REFERENCES
1. Higuchi M, Tanaka E, Kiyosawa K. Epidemiology and clinical aspects on hepatitis C. Jpn J Infect Dis 2002;55:69–77.
2. Arii S, Sata M, Sakamoto M, et al. Management of hepatocellular carcinoma: report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010;40:667–85.
3. Nouhaud E, Créhange G, Cueff A, et al. Stereotactic body radiotherapy for liver tumors with or without rotational intensity modulated radiation therapy. BMC Res Notes 2013;6:492.
4. Yamashita H, Nakagawa K, Shiraishi K, et al. Radiotherapy for lymph node metastases in patients with hepatocellular carcinoma: retrospective study. J Gastroenterol Hepatol 2007;22:523–7.
5. Garrean S, Hering J, Saied A, et al. Radiofrequency ablation of primary and metastatic liver tumors: a critical review of the literature. Am J Surg 2008;195:508–20.
6. Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002;53:810–21.
7. Ikai I, Kudo M, Arii S, et al. Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol Res 2010;40:1043–59.
8. Rhim H, Lim HK. Radiofrequency ablation for hepatocellular carcinoma abutting the diaphragm: the value of artificial ascites. Abdom Imaging 2009;34:371–80.
9. Torzilli G, Makuuchi M, Inoue K, et al. No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach. Arch Surg 1999;134:984–92.
10. Lin SM, Lin CJ, Lin CC, et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005;54:1151–6.
11. Yamashita H, Nakagawa K, Shiraishi K, et al. External beam radiotherapy to treat intra- and extra-hepatic dissemination of hepatocellular carcinoma after radiofrequency thermal ablation. J Gastroenterol Hepatol 2006;21:1555–60.
12. Yamashita H, Onishi H, Matsumoto Y, et al. Local effect of stereotactic body radiotherapy for primary and metastatic liver tumors in 130 Japanese patients. Radiat Oncol 2014;9:112.
13. Murakami T, Imai Y, Okada M, et al. Ultrasonography, computed tomography and magnetic resonance imaging of hepatocellular carcinoma: toward improved treatment decisions. Oncology 2011;81 Suppl 1:86–99.
14. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–2.
15. EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908–43.
16. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52–60.
17. Andolino DL, Johnson CS, Maluccio M, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011;81:e447–53.
18. Louis C, Dewas S, Mirabel X, et al. Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results. Technol Cancer Res Treat 2010;9:479–87.
19. Nouhaud E, Créhange G, Cueff A, et al. Stereotactic body radiotherapy for liver tumors with or without rotational intensity modulated radiation therapy. BMC Res Notes 2013;6:492.
20. Ibarra RA, Rojas D, Snyder L, et al. Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors. Acta Oncol 2012;51:575–83.
21. Bujold A, Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013;31:1631–9.
22. Cardenes HR, Price TR, Perkins SM, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 2010;12:218–25.
23. Takeda A, Sanuki N, Eriguchi T, et al. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. J Gastroenterol Hepatol 2010;30:324–9.
24. Poon RT, Ng IO, Fan ST, et al. Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. J Clin Oncol 2001;19:3037–44.
25. Arii S, Tanaka J, Yamazoe Y, et al. Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy. Cancer 1992;69:913–9.
26. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200–7.